Biotechnology company Amyris has launched a Baby Cream To Powder product under its Pipette baby brand, which it describes as a safe alternative to talc-based baby powder.
The launch announcement comes a mere day after beauty giant Johnson & Johnson revealed that it would stop selling Johnson’s Baby Powder in North America amid questions about its safety. J&J is currently facing multiple lawsuits from cancer sufferers alleging that asbestos traces in its classic talc product made them unwell.
The Baby Cream To Powder’s creamy format makes it easier to apply to hard-to-reach baby rolls than traditional powder products, according to Amyris, and, once on the skin, it transforms into a silky powder, eliminating the risk of powder inhalation.
The main ingredient is 100% sugarcane-derived squalane, which is said to provide weightless hydration. Mango seed butter, meanwhile, provides antioxidant protection.
"Our Pipette and clean skin care consumer brands are experiencing very strong growth," said John Melo, President and Chief Executive Officer of Amyris.
"Based on current demand, we believe the consumer business has the potential to reach over US$90m in revenue for 2020.
“Consumers are focusing on healthy skin for themselves and their family, and have moved their purchasing online. Sugarcane derived squalane is now clinically proven to provide significant nourishment for the skin microbiome, and we are very pleased to meet a critical need for the consumer at a time when the skin needs it most."
